{
    "nctId": "NCT01875367",
    "briefTitle": "Phase III to Evaluate Patient\u00b4s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer",
    "officialTitle": "Phase III Trial to Evaluate Patient\u00b4s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 166,
    "primaryOutcomeMeasure": "Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Woman, 18 years old or upper.\n* Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive histologically confirmed. The criteria for positivity HER 2 are:\n\n  1. immuno-histochemistry (IHC) 3+ (\\>10% of tumor cells with complete and intense membrane staining)\n  2. IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (\\*)\n  3. FISH / CISH / SISH + for HER 2 amplification (\\*) (\\*) Defined as the ratio of copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)\\> 2.2, or a number of copies of HER 2/neu\\> 6, as per local laboratory criteria.\n* Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at least 4 months.\n* No evidence of disease progression (clinical and / or radiological) for at least 4 months before inclusion in the study and with a life expectancy of at least 3 months.\n* Adequate performance status: Eastern Cooperative Oncology Group (ECOG) \\<2.\n* Adequate bone marrow function, liver and kidney\n* Proper cardiac function (LVEF within normal limits the center, measured by echocardiography or MUGA).\n* The patient must have been informed of the study and must sign and date informed consent document for entry into the trial.\n* The patient must be willing and able to comply with study procedures and be available to answer the study questionnaires.\n\nExclusion Criteria:\n\n* Patients with no advanced breast cancer.\n* Breast cancer patients with tumors HER 2-negative.\n* The patient has another active malignancy other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear\\> 5 years without evidence of disease could be included.\n* The patient has uncontrolled brain metastases.\n* Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.\n* Known hypersensitivity to trastuzumab or to any of its components.\n* Patients with severe dyspnea at rest or requiring supplemental oxygen.\n* Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction on ECG or hypertension poorly controlled.\n* Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).\n* The patient is pregnant or lactating. Women of childbearing potential should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}